When does B12 level warrant supplementation vs injections?

How it works

Sublingual and buccal mucosal absorption is minor; most absorption happens after swallowing the dose, via the same passive-diffusion gut absorption mechanism. The supplement-industry framing of sublingual as categorically superior is not supported by trial evidence; choose between sublingual and oral on cost, tolerability, and palatability rather than mechanism. Intramuscular hydroxocobalamin bypasses GI absorption entirely; serum B12 rises within 24-48 hours.

Effective dose

Hydroxocobalamin is preferred over cyanocobalamin in UK parenteral practice due to longer tissue retention. The US-style schedule sometimes encountered (1000 mcg every other day for 2 weeks, then weekly for 1 month, then monthly) is not the UK schedule. Anyone presenting in UK clinical care with a US-style ongoing schedule should have it reviewed for alignment with UK practice. The 1000 mcg/day oral regimen reflects passive-diffusion mechanism: 1-2% of 1000 mcg gives around 10-20 mcg absorbed daily, well above the 1.5 mcg/day SACN RNI.

Forms compared

Sublingual products (1000-5000 mcg): work via the same passive-diffusion mechanism as swallowed oral tablets after swallowing; buccal mucosal absorption is minor. Patches and nasal sprays: available commercially; not in current UK NHS clinical practice; limited evidence base; not recommended as primary intervention for diagnosed deficiency without specific clinical reason.

Timing

Reticulocyte response within 7-10 days of starting effective B12 (earliest objective sign). MCV and Hb recovery over 6-8 weeks. Neurological recovery slower and partial. NICE NG239 (March 2024) explicitly: B12 repletion must not be delayed pending test results when neurological symptoms are present.

Safety profile

NICE NG239 (March 2024) explicitly states the urgency principle: B12 repletion must not be delayed pending test results when neurological symptoms are present, because long-standing nerve damage may not fully reverse. Pernicious anaemia: lifelong replacement required; do not stop without specialist input. The clinical principle: when in doubt with neurological signs, start B12 (parenteral hydroxocobalamin); investigate cause in parallel.

Special populations

Pregnancy and breastfeeding: standard B12 repletion per NICE NG239; hydroxocobalamin is the established UK parenteral agent. Bariatric surgery users: lifelong supplementation required; protocols vary by procedure and unit (sleeve gastrectomy and Roux-en-Y typically require B12 monitoring and replacement). Renal impairment: standard adult dosing; hydroxocobalamin preferred over cyanocobalamin theoretically (cyanide moiety) at very high doses, though clinical significance limited at standard supplement doses.

Interactions

Nitrous oxide exposure (recreational or anaesthetic): inactivates B12 by oxidising the cobalt centre; can precipitate functional B12 deficiency. Folate co-supplementation during acute B12 repletion: folic acid 5 mg/day for 4 weeks is sometimes added to address functional folate deficiency from accelerated red cell production, but B12 must be confirmed and repletion started first or alongside.

Guideline positions

Wang 2018 Cochrane: high-dose oral B12 may be as effective as IM at restoring haematological and short-term neurological responses; limited evidence base (3 RCTs total). NICE NG239 (March 2024) is the first major UK guideline to formally consider oral as an option in non-malabsorption cases. UK schedules per NICE NG239, NICE CKS, BNF: 1 mg three times weekly for 2 weeks then 2-3 monthly (no neurological involvement); 1 mg alternate days until no improvement then 2 monthly (with neurological involvement). Hydroxocobalamin preferred in UK parenteral practice over cyanocobalamin.

Practical framework

Routine re-checking of serum B12 in users on established replacement is NOT recommended (NICE CKS, BNF); level rises mechanically with dose. Clinical review focuses on symptom response, FBC trajectory (reticulocyte rise within 7-10 days, MCV and Hb recovery), and consideration of MMA in unclear cases. UK NICE first-line oral preparation is cyanocobalamin tablets, prescribable. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: routine re-checking serum B12 on therapy confirms response. Once supplementation is ongoing, serum B12 rises mechanically with the dose; functional markers (MMA, homocysteine) and clinical response are more meaningful.

Claim: US-style ongoing schedules (1000 mcg every other day for 2 weeks, then weekly for 1 month, then monthly) reflect UK practice. UK practice per NICE NG239 / BNF / NICE CKS uses different schedules with hydroxocobalamin (not cyanocobalamin) as the parenteral agent.

Claim: oral is never sufficient for pernicious anaemia. High-dose oral can raise serum B12 in pernicious anaemia via passive diffusion, but UK first-line for confirmed pernicious anaemia remains IM hydroxocobalamin.